Completed PHASE3 INTERVENTIONAL 2-arm NCT00468312

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis

Sponsor: Organon and Co

Conditions Seasonal Allergic Rhinitis

Interventions Mometasone furoate nasal spray Placebo

Updated 6 times since 2017 Last updated: Feb 7, 2022 Started: Mar 31, 2007 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Seasonal Allergic Rhinitis and is currently completed. Organon and Co leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.